tiprankstipranks
Trending News
More News >

Bright Minds assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Bright Minds (DRUG) with an Overweight rating and no price target Bright Minds’ lead asset, BMB-101, is a highly selective 5-HT2C receptor agonist in developmental and epileptic encephalopathies and absence epilepsy, the analyst tells investors in a research note. BMB-101 may deliver improved efficacy, safety, and durability vs. competitors, the firm says.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1